Patupilone
- Generic Name
- Patupilone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H41NO6S
- CAS Number
- 152044-54-7
- Unique Ingredient Identifier
- UEC0H0URSE
- Background
Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol.
- Indication
Investigated for use/treatment in ovarian cancer, lung cancer, brain cancer, breast cancer, and gastric cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT00273312
- Locations
- ๐จ๐ณ
Novartis Investigative Site, Tai Chung Municipality, Taiwan
Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT00219297
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
๐บ๐ธCleveland Clinic Foundation, Cleveland, Ohio, United States
๐บ๐ธUniversity of California Davis Cancer Center UC Davis Cancer (3), Sacramento, California, United States
Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-02-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 89
- Registration Number
- NCT00171834
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธEllis Fisher Cancer Center, Columbia, Missouri, United States
๐บ๐ธHillman Cancer Center, Pittsburg, Pennsylvania, United States
EPO906 Therapy in Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT00035087
- Locations
- ๐บ๐ธ
Cancer Institute of New Jersey (CINJ), New Brunswick, New Jersey, United States
EPO906 Therapy in Patients With Advanced Melanoma
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2012-04-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT00035165
- Locations
- ๐บ๐ธ
Comprehensive Cancer Center@ Our Lady if Mercy Medical Center, Bronx, New York, United States
๐บ๐ธUniversity of Colorado, Aurora, Colorado, United States
๐บ๐ธH. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
EPO906 Therapy in Patients With Advanced Kidney Cancer
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2012-04-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 53
- Registration Number
- NCT00035243
- Locations
- ๐บ๐ธ
Cleveland Clinic Foundation, Cleveland, Ohio, United States
๐ซ๐ทCentre L. Berard, Lyon, France
๐บ๐ธUCLA Medical Center, Los Angeles, California, United States
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT00035100
- Locations
- ๐ฌ๐ง
Novartis Investigative Site, Surrey, United Kingdom
EPO906 Therapy in Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT00035113
- Locations
- ๐บ๐ธ
Pacific Shores Medical Group, Long Beach, California, United States
๐บ๐ธUniversity of Maryland - Greenbaum Cancer Center, Baltimore, Maryland, United States
๐บ๐ธCalifornia Pacific Medical Center, San Francisco, California, United States
EPO906 Therapy in Patients With Advanced Breast Cancer
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 46
- Registration Number
- NCT00035126
- Locations
- ๐บ๐ธ
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
๐บ๐ธCancer Institute of New Jersey (CINJ), New Brunswick, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.